PI3K beta inhibitor GSK2636771

Drug Overview

PI3K beta inhibitor GSK2636771 is a specialized medication used in the field of precision oncology. It is a type of Targeted Therapy often described as a “Smart Drug.” Unlike standard chemotherapy that attacks all fast-growing cells, this medication is designed to seek out and block specific signals inside cancer cells that have a very particular genetic mistake.

By focusing on a single part of the cell’s “engine,” this drug aims to stop the cancer from growing while causing less damage to healthy parts of the body. It is currently being studied in international clinical trials to help patients with advanced tumors that have not responded to other treatments.

• Generic Name: GSK2636771
• US Brand Names: None (Currently an investigational drug)
• Drug Class: PI3K-beta selective inhibitor; Targeted Therapy
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Not FDA Approved (Available only through clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how GSK2636771 works, think of a cancer cell as having a series of “on” switches that tell it to grow and divide. One of the most important switches is called PI3K (Phosphoinositide 3-kinase).

At the molecular level, GSK2636771 works through a very specific process:

Targeting the Beta Isoform

The PI3K protein comes in different versions, or “isoforms.” This drug specifically targets the beta β isoform. In many cancers, especially those that have lost a protective protein called PTEN, the beta isoform is stuck in the “ON” position.

Blocking the Signal

When GSK2636771 enters the cancer cell, it binds directly to the PI3K-beta enzyme. By doing this, it stops the production of a signaling molecule called PIP3.

Stopping Growth

Without PIP3, the cell cannot activate a secondary protein called Akt. This interrupts the PI3K/Akt/mTOR pathway, which is the cell’s primary “growth command center.”

Once this pathway is blocked, the cancer cell can no longer copy its DNA or grow. It eventually becomes weak and may undergo a process of self-destruction called apoptosis.

FDA-Approved Clinical Indications

As of early 2026, GSK2636771 has not received full FDA approval. It is strictly used in research settings for specific patients.

Oncological Uses (Investigational):

• PTEN-Deficient Solid Tumors: Cancers that have lost the PTEN gene, including certain types of prostate, breast, and lung cancer.
• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Often studied in combination with other hormone therapies.
• Advanced Malignant Neoplasms: For patients who have failed standard care.

Non-oncological Uses:

• None.

Dosage and Administration Protocols

In clinical trials, GSK2636771 is taken as a tablet by mouth. The exact dose is determined by the specific trial protocol.

• Dose Adjustments: If a patient develops high blood sugar or severe skin rashes, the doctor may lower the dose. Currently, there is limited data on specific adjustments for renal (kidney) or hepatic (liver) insufficiency, but these patients are monitored very closely.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 has focused on how well this drug works when matched with the right genetic profile.

• PTEN-Deficient Success: In Phase 1 and 2 studies, patients with tumors lacking the PTEN gene showed a higher “Clinical Benefit Rate” compared to those with a normal PTEN gene.
• Numerical Data: Research has shown that in specific groups of prostate cancer patients, using this drug alongside hormone therapy can lead to a “Partial Response” (tumor shrinkage) in approximately 15-20% of cases where standard drugs had stopped working.
• Disease Control: Many patients achieved “Stable Disease,” meaning their cancer stopped growing for several months. Numerical data indicates a median progression-free survival of approximately 3.5 to 5 months in heavily pre-treated populations.

Safety Profile and Side Effects

Because PI3K also helps the body manage sugar, the side effects of this drug are very different from standard chemotherapy.

Black Box Warning:

• None (Experimental drugs do not have a Black Box Warning until they are FDA-approved).

Common Side Effects (>10%)

• Gastrointestinal Issues: Diarrhea, nausea, and stomach pain.
• Hyperglycemia: High blood sugar (since PI3K helps insulin work).
• Skin Rash: Redness or itching of the skin.
• Fatigue: A general feeling of tiredness.

Serious Adverse Events

• Severe Diarrhea: This can lead to dehydration and kidney stress.
• Liver Enzyme Elevation: Signalling potential stress on the liver.
• Pneumonitis: A rare but serious inflammation of the lungs.

Management Strategies

• Sugar Monitoring: Patients must check their blood sugar levels regularly.
• Skin Care: Using fragrance-free moisturizers can help manage mild rashes.

Research Areas

In the fields of Immunotherapy and regenerative medicine, researchers are exploring “Combination Strategies.” Studies are looking at whether blocking the PI3K-beta pathway can make “cold” tumors “hot,” meaning it makes the cancer easier for the body’s immune system to find. Current research is testing GSK2636771 alongside Immune Checkpoint Inhibitors to see if this helps the body’s regenerating immune cells attack the tumor more effectively.

Disclaimer: These findings regarding GSK2636771, PI3K-beta inhibition, and checkpoint inhibitor combinations are still evolving and are not yet applicable to practical or professional clinical scenarios. While early studies support immune microenvironment remodeling and improved T-cell trafficking, claims of consistent cold-to-hot conversion or routine clinical efficacy remain exploratory and should be interpreted cautiously.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Genetic Testing: To confirm if the tumor is “PTEN-deficient.”
• Fasting Glucose/HbA1c: To establish a baseline for blood sugar.
• Liver and Kidney Function: Standard blood panels to check organ health.

Precautions During Treatment

• Monitor Blood Sugar: Patients with diabetes must be extra careful, as this drug can cause sugar levels to spike.
• Hydration: Drink plenty of water to help manage diarrhea.

“Do’s and Don’ts” List

• DO report any new shortness of breath or cough immediately.
• DO take the medication at the same time every day to keep the drug levels steady.
• DON’T stop taking the medication without talking to your trial doctor, even if you feel tired.
• DON’T take new over-the-counter supplements without checking, as they may interfere with the drug.

Legal Disclaimer

The medical information provided in this guide is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. GSK2636771 is an investigational drug and is only available through clinical trials. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or participation in clinical research.